Study to confirm fatty liver and build fibrosis test markers
Part of Digestive system clinical trials.
This study enrolls people with confirmed fatty liver to help researchers create and validate tests that may estimate liver scarring (fibrosis). It focuses on collecting medical information and verifying the liver condition using lab/scan results, which could help improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of fatty liver on a biopsy (tissue sample) or on imaging like ultrasound/CT/MRI.
- You should not have a history of heavy alcohol use.
- You should not have viral hepatitis (like hepatitis B or C).
- You should not have autoimmune hepatitis or other immune-caused liver inflammation.
- You should not have certain genetic/metabolic liver conditions (for example hemochromatosis, Wilson disease, or alpha-1 antitrypsin deficiency).
- You should not be taking medications known to harm the liver (examples given include amiodarone).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks for better ways to detect liver scarring (fibrosis) in people with long-term liver disease. It may help find problems earlier.
This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.
This study looks at how the liver's immune environment changes in people with non-alcoholic fatty liver disease (NAFLD) that has progressed to significant scarring. Researchers will use a liver biopsy to understand the inflammation better, which may lead to new treatments.
This study tests a way to find liver scarring (fibrosis) early in people who have risk factors like being overweight, having type 2 diabetes, or drinking alcohol heavily. Early detection may help prevent serious liver damage.
This study looks at how common fatty liver disease and liver scarring are in people with lupus. It may help doctors understand if lupus patients have a higher risk for liver problems.
This study compares two non-invasive approaches to diagnose advanced liver scarring in people with non-alcohol-related fatty liver disease (NAFLD). It may help confirm which test strategy finds advanced scarring without needing a biopsy for everyone.
Hear when a new Fibrosis of Liver trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.